Patent: 10,786,552
✉ Email this page to a colleague
Summary for Patent: 10,786,552
Title: | Il-2R.beta.-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody |
Abstract: | The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R.beta.-activating amount of a long acting, IL-2R.beta.-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody. |
Inventor(s): | Addepalli; Murali Krishna (Secunderabad, IN), Charych; Deborah H. (Albany, CA), Kantak; Seema (Pacifica, CA), Lee; Steven Robert (San Lorenzo, CA) |
Assignee: | Nektar Therapeutics (San Francisco, CA) |
Application Number: | 15/997,487 |
Patent Claims: | see list of patent claims |
Details for Patent 10,786,552
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2034-02-21 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2034-02-21 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2034-02-21 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2034-02-21 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | ⤷ Try a Trial | 2034-02-21 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 08/27/2021 | ⤷ Try a Trial | 2034-02-21 |
Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 05/18/2016 | ⤷ Try a Trial | 2034-02-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |